238 related articles for article (PubMed ID: 31248688)
21. Impact of human papillomavirus (HPV) vaccination on HPV 16/18-related prevalence in precancerous cervical lesions.
Powell SE; Hariri S; Steinau M; Bauer HM; Bennett NM; Bloch KC; Niccolai LM; Schafer S; Unger ER; Markowitz LE
Vaccine; 2012 Dec; 31(1):109-13. PubMed ID: 23137842
[TBL] [Abstract][Full Text] [Related]
22. Rationale and design of a long term follow-up study of women who did and did not receive HPV 16/18 vaccination in Guanacaste, Costa Rica.
Gonzalez P; Hildesheim A; Herrero R; Katki H; Wacholder S; Porras C; Safaeian M; Jimenez S; Darragh TM; Cortes B; Befano B; Schiffman M; Carvajal L; Palefsky J; Schiller J; Ocampo R; Schussler J; Lowy D; Guillen D; Stoler MH; Quint W; Morales J; Avila C; Rodriguez AC; Kreimer AR;
Vaccine; 2015 Apr; 33(18):2141-51. PubMed ID: 25796338
[TBL] [Abstract][Full Text] [Related]
23. Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial.
Lehtinen M; Paavonen J; Wheeler CM; Jaisamrarn U; Garland SM; Castellsagué X; Skinner SR; Apter D; Naud P; Salmerón J; Chow SN; Kitchener H; Teixeira JC; Hedrick J; Limson G; Szarewski A; Romanowski B; Aoki FY; Schwarz TF; Poppe WA; De Carvalho NS; Germar MJ; Peters K; Mindel A; De Sutter P; Bosch FX; David MP; Descamps D; Struyf F; Dubin G;
Lancet Oncol; 2012 Jan; 13(1):89-99. PubMed ID: 22075171
[TBL] [Abstract][Full Text] [Related]
24. UK population based study to predict impact of HPV vaccination.
Hibbitts S; Tristram A; Beer H; McRea J; Rose B; Hauke A; Nuttall D; Dallimore N; Newcombe RG; Fiander A
J Clin Virol; 2014 Feb; 59(2):109-14. PubMed ID: 24388208
[TBL] [Abstract][Full Text] [Related]
25. Impact of human papillomavirus vaccination on the clinical meaning of cervical screening results.
Castle PE; Xie X; Xue X; Poitras NE; Lorey TS; Kinney WK; Wentzensen N; Strickler HD; Burger EA; Schiffman M
Prev Med; 2019 Jan; 118():44-50. PubMed ID: 30316878
[TBL] [Abstract][Full Text] [Related]
26. Monitoring Effect of Human Papillomavirus Vaccines in US Population, Emerging Infections Program, 2008-2012.
Hariri S; Markowitz LE; Bennett NM; Niccolai LM; Schafer S; Bloch K; Park IU; Scahill MW; Julian P; Abdullah N; Levine D; Whitney E; Unger ER; Steinau M; Bauer HM; Meek J; Hadler J; Sosa L; Powell SE; Johnson ML;
Emerg Infect Dis; 2015 Sep; 21(9):1557-61. PubMed ID: 26291379
[TBL] [Abstract][Full Text] [Related]
27. Real-world effectiveness of HPV vaccination against cervical neoplasia among birth cohorts ineligible for routine vaccination.
Dong L; Nygård M; Støer NC; Klungsøyr O; Hansen BT
Int J Cancer; 2023 Jul; 153(2):399-406. PubMed ID: 36866965
[TBL] [Abstract][Full Text] [Related]
28. Cervical intraepithelial neoplasia grade 2 or worse in Galicia, Spain: HPV 16 prevalence and vaccination impact.
Pérez-Castro S; Lorenzo-Mahía Y; Iñarrea Fernández A; Lamas-González MJ; Sarán-Díez MT; Rubio-Alarcón J; Reboredo-Reboredo MC; Mosteiro-Lobato S; López-Miragaya I; Torres-Piñón J; Melón-García S
Enferm Infecc Microbiol Clin; 2014 Oct; 32(8):479-85. PubMed ID: 24274937
[TBL] [Abstract][Full Text] [Related]
29. Early effect of the HPV vaccination programme on cervical abnormalities in Victoria, Australia: an ecological study.
Brotherton JM; Fridman M; May CL; Chappell G; Saville AM; Gertig DM
Lancet; 2011 Jun; 377(9783):2085-92. PubMed ID: 21684381
[TBL] [Abstract][Full Text] [Related]
30. Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women.
Muñoz N; Kjaer SK; Sigurdsson K; Iversen OE; Hernandez-Avila M; Wheeler CM; Perez G; Brown DR; Koutsky LA; Tay EH; Garcia PJ; Ault KA; Garland SM; Leodolter S; Olsson SE; Tang GW; Ferris DG; Paavonen J; Steben M; Bosch FX; Dillner J; Huh WK; Joura EA; Kurman RJ; Majewski S; Myers ER; Villa LL; Taddeo FJ; Roberts C; Tadesse A; Bryan JT; Lupinacci LC; Giacoletti KE; Sings HL; James MK; Hesley TM; Barr E; Haupt RM
J Natl Cancer Inst; 2010 Mar; 102(5):325-39. PubMed ID: 20139221
[TBL] [Abstract][Full Text] [Related]
31. Effectiveness on high-grade cervical abnormalities and long-term safety of the quadrivalent human papillomavirus vaccine in Japanese women.
Sakamoto M; Miyagi E; Sumi Y; Aisaka K; Kuno N; Nagano H; Asahara S; Han SR; Wakana A; Murata S; Sawata M; Tanaka Y
J Infect Chemother; 2019 Jul; 25(7):520-525. PubMed ID: 30879979
[TBL] [Abstract][Full Text] [Related]
32. Early impact of human papillomavirus vaccination on cervical neoplasia--nationwide follow-up of young Danish women.
Baldur-Felskov B; Dehlendorff C; Munk C; Kjaer SK
J Natl Cancer Inst; 2014 Mar; 106(3):djt460. PubMed ID: 24552678
[TBL] [Abstract][Full Text] [Related]
33. Human papillomavirus vaccination history among women with precancerous cervical lesions: disparities and barriers.
Mehta NR; Julian PJ; Meek JI; Sosa LE; Bilinski A; Hariri S; Markowitz LE; Hadler JL; Niccolai LM
Obstet Gynecol; 2012 Mar; 119(3):575-81. PubMed ID: 22353956
[TBL] [Abstract][Full Text] [Related]
34. Declining rates of high-grade cervical lesions in young women in Connecticut, 2008-2011.
Niccolai LM; Julian PJ; Meek JI; McBride V; Hadler JL; Sosa LE
Cancer Epidemiol Biomarkers Prev; 2013 Aug; 22(8):1446-50. PubMed ID: 23704476
[TBL] [Abstract][Full Text] [Related]
35. The effects of the national HPV vaccination programme in England, UK, on cervical cancer and grade 3 cervical intraepithelial neoplasia incidence: a register-based observational study.
Falcaro M; Castañon A; Ndlela B; Checchi M; Soldan K; Lopez-Bernal J; Elliss-Brookes L; Sasieni P
Lancet; 2021 Dec; 398(10316):2084-2092. PubMed ID: 34741816
[TBL] [Abstract][Full Text] [Related]
36. Effectiveness of 1, 2, and 3 Doses of Human Papillomavirus Vaccine Against High-Grade Cervical Lesions Positive for Human Papillomavirus 16 or 18.
Johnson Jones ML; Gargano JW; Powell M; Park IU; Niccolai LM; Bennett NM; Griffin MR; Querec T; Unger ER; Markowitz LE;
Am J Epidemiol; 2020 Apr; 189(4):265-276. PubMed ID: 31680146
[TBL] [Abstract][Full Text] [Related]
37. Potential impact of nonavalent HPV vaccine in the prevention of high-grade cervical lesions and cervical cancer in Portugal.
Pista A; de Oliveira CF; Lopes C; Cunha MJ;
Int J Gynaecol Obstet; 2017 Oct; 139(1):90-94. PubMed ID: 28632949
[TBL] [Abstract][Full Text] [Related]
38. HPV catch-up vaccination of young women: a systematic review and meta-analysis.
Couto E; Sæterdal I; Juvet LK; Klemp M
BMC Public Health; 2014 Aug; 14():867. PubMed ID: 25149765
[TBL] [Abstract][Full Text] [Related]
39. Fraction of high-grade cervical intraepithelial lesions attributable to genotypes targeted by a nonavalent HPV vaccine in Galicia, Spain.
Perez S; Iñarrea A; Pérez-Tanoira R; Gil M; López-Díez E; Valenzuela O; Porto M; Alberte-Lista L; Peteiro-Cancelo MA; Treinta A; Carballo R; Reboredo MC; Alvarez-Argüelles ME; Purriños MJ
Virol J; 2017 Nov; 14(1):214. PubMed ID: 29110680
[TBL] [Abstract][Full Text] [Related]
40. Cervical Intraepithelial Neoplasia Rates in British Columbia Women: A Population-Level Data Linkage Evaluation of the School-Based HPV Immunization Program.
Racey CS; Albert A; Donken R; Smith L; Spinelli JJ; Pedersen H; de Bruin P; Masaro C; Mitchell-Foster S; Sadarangani M; Dawar M; Krajden M; Naus M; van Niekerk D; Ogilvie G
J Infect Dis; 2020 Jan; 221(1):81-90. PubMed ID: 31504649
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
